Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach

Heading

Abstract

Objective. Little information on the population pharmacokinetics of the tricyclic antidepressant doxepine and its pharmacologically active metabolite desmethyldoxepine is available. However, a more individualised drug therapy may be feasible if the influence of various patient characteristics on plasma concentration was known.

Patients and methods. We retrospectively analysed pharmacokinetic therapeutic drug-monitoring data in 114 psychiatric patients (79 females, 35 males) treated with doxepine for a period of 22–306 days, mostly due to major depression. The data were analysed using the computer program NONMEM. For both, doxepine and its metabolite desmethyldoxepine, a one-compartment model was chosen. Pharmacokinetic parameters clearance (CL/F) and volume of distribution (V/F) of doxepine and desmethyldoxepine were modelled in terms of both random and fixed effects.

Results. The fit of the model to the concentration–time data was significantly improved when V/F was expressed as a function of weight (P<0.05) and CL/F as a function of age (P<0.05). Co-medication that inhibits P ₄₅₀ isoenzymes lowered CL/F of doxepine by 15%.

Conclusion. The analysis indicates that the factors age and, to some extent, body weight may be a guidance for individual doxepine dose regimens, which however needs confirmation in prospective clinical trials linking pharmacokinetics and therapeutic effect. Co-medication may represent only a minor important covariate.